Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis
In adults with idiopathic pulmonary fibrosis, the addition of cotrimoxazole or doxycycline to usual care did not significantly improve the time to unselected respiratory hospitalization or death compared with usual care alone. These findings do not support treatment with these antibiotics for the underlying disease.
Martinez FJ, Yow E, Flaherty KR, et al. Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial. Jama. 2021; 325(18): 1841-1851. doi: 10.1001 / jama.2021.4956
Commentary
The purpose of this study was to determine if antimicrobial therapy in addition to usual care significantly improved clinical outcomes. The results were not statistically significant according to a randomized clinical trial conducted on 513 adults with idiopathic pulmonary fibrosis compared to a single treatment plan.
The dosage was stated as trimoxazole (trimethoprim 160 mg / sulfamethoxazole 800 mg twice daily + folic acid 5 mg twice daily) or doxycycline (100 mg once daily if body weight is less than 50 kg, 100 mg twice daily if body weight is more than 50 kg).
